All In Biotech

Drug Trial Radar · NCT01379677

Rubidium-82 PET and Tc-99m-MIBI SPET: A Head to Head Comparison

Diagnosis of Coronary Artery Disease With Rubidium-82 PET and Technetium-99m-MIBI SPET: A Head to Head Comparison, Versus Coronary CT Angiography

Last checked: Nov 19, 2026Latest source record: May 14, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

135

Actual

Start

Feb 2011

Primary completion

Nov 2013

Study completion Nov 2013

Sponsor

Lead sponsor
Advanced Accelerator ApplicationsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 23, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to compare myocardial perfusion imaging using Rubidium-82 PET with Tc-99m-MIBI SPET, in the evaluation of significant Coronary Artery Disease (CAD).

Conditions

  • Coronary Artery Disease

Interventions

  • Rubidium-82Drug

    Maximum dose allowed per injection: 2200 MBq Maximum cumulated dose allowed per examination: 4400 MBq Intravenous Use

  • Sestamibi. reconstitution with sodium pertechnetate (99mTc)Drug

    Maximum dose allowed per injection: 1000 MBq Intravenous Use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The specificity of detecting significant coronary artery disease (as defined as being >70% stenosis, on coronary CT angiography)Time frame: Up to 2 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University College Hospital London NHS Foundation Trust

    London, London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.